周四盘前，新冠疫苗生产商BioNTech SE（BNTX）股价大跌5.10%，主要受到其合作伙伴辉瑞（PFE）计划出售所持全部股份的消息影响。
据知情人士透露，辉瑞正寻求通过隔夜大宗交易出售约455万份BioNTech的美国存托凭证（ADR），每股定价区间为108至111.70美元。若以价格区间上限计算，此次股权出售将为辉瑞带来约5.08亿美元收益。这一举动标志着新冠疫情期间最具盈利性的合作关系正逐渐走向尾声。
辉瑞与BioNTech的合作始于2020年，双方共同开发的COVID-19疫苗在全球创下数百亿美元的收入。然而，随着疫情的结束，两家公司都在寻求新的发展方向。辉瑞上周以100亿美元收购了肥胖症初创企业Metsera Inc.，部分目的是用重磅减肥药替代日益萎缩的新冠业务收入。而BioNTech则回归其最初的癌症治疗研发主线，并与百时美施贵宝达成了价值高达111亿美元的合作协议。尽管如此，两家公司仍将基于BioNTech的专有mRNA技术继续合作开发COVID-19疫苗配方，并共享收益。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.